Vitality Biopharma (OTCMKTS:VBIO) and US Stem Cell (OTCMKTS:USRM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.
This is a summary of current recommendations and price targets for Vitality Biopharma and US Stem Cell, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|US Stem Cell||0||0||0||0||N/A|
Earnings and Valuation
This table compares Vitality Biopharma and US Stem Cell’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Vitality Biopharma||$100,000.00||188.10||-$4.30 million||N/A||N/A|
|US Stem Cell||$5.52 million||1.30||-$3.48 million||N/A||N/A|
US Stem Cell has higher revenue and earnings than Vitality Biopharma.
Risk & Volatility
Vitality Biopharma has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500. Comparatively, US Stem Cell has a beta of 5.91, suggesting that its stock price is 491% more volatile than the S&P 500.
Institutional and Insider Ownership
0.2% of Vitality Biopharma shares are owned by institutional investors. 8.7% of Vitality Biopharma shares are owned by company insiders. Comparatively, 16.7% of US Stem Cell shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Vitality Biopharma and US Stem Cell’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|US Stem Cell||-21.01%||N/A||-66.41%|
US Stem Cell beats Vitality Biopharma on 7 of the 9 factors compared between the two stocks.
About Vitality Biopharma
Vitality Biopharma, Inc. engages in the development of cannabinoid pharmaceuticals for the treatment of neurological and inflammatory disorders in the United States. The company's products in pipeline include VBX-100, an oral cannabinoid formulation for inflammatory bowel disease, C.difficile-associated diarrhea and colitis, and narcotic bowel syndrome; and VBX-210, a cannabinoid formulation, which is in preclinical studies for the treatment of gastrointestinal conditions. It develops additional cannabinoid product formulations for refractory pain and autism spectrum disorder. The company was formerly known as Stevia First Corp. and changed its name to Vitality Biopharma, Inc. in July 2016. The company was founded in 2007 and is based in Los Angeles, California.
About US Stem Cell
U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training services, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.
Receive News & Ratings for Vitality Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitality Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.